Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$49.45 +3.0%	$25.04	$10.14 ▼ $56.83	$603.78M	0.79	166,729 shs	3.75 million shs
COLL Collegium Pharmaceutical	$29.93 +0.1%	$28.86	$23.23 ▼ $42.29	$961.65M	0.63	397,319 shs	315,470 shs
MLYS Mineralys Therapeutics	$13.71 -2.1%	$14.88	$8.24 ▼ $18.38	$893.62M	-0.18	537,319 shs	2.23 million shs
NTLA Intellia Therapeutics	$9.56 -0.5%	$8.56	$5.90 ▼ $28.18	$990.23M	2.15	2.91 million shs	4.00 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	+135.25%	+124.16%	+129.57%	+314.15%
COLL Collegium Pharmaceutical	0.00%	+0.34%	+1.84%	+0.27%	-7.05%
MLYS Mineralys Therapeutics	0.00%	+1.71%	-12.84%	-13.66%	+17.18%
NTLA Intellia Therapeutics	0.00%	+3.91%	+36.77%	+34.46%	-57.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.7949 of 5 stars	3.6	2.0	4.6	3.1	0.0	0.0
COLL Collegium Pharmaceutical	3.9843 of 5 stars	3.4	1.0	3.0	1.5	0.8	2.5
MLYS Mineralys Therapeutics	2.1458 of 5 stars	3.4	1.0	0.0	1.6	4.2	0.0
NTLA Intellia Therapeutics	4.6212 of 5 stars	4.3	3.0	4.7	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$55.43	12.09% Upside
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	46.17% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	135.23% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	249.04% Upside

Current Analyst Ratings Breakdown

Latest CDTX, COLL, MLYS, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	475.42	N/A	N/A	$14.92 per share	3.31
COLL Collegium Pharmaceutical	$631.45M	1.52	$12.37 per share	2.42	$7.10 per share	4.22
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
NTLA Intellia Therapeutics	$57.88M	17.11	N/A	N/A	$8.56 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
COLL Collegium Pharmaceutical	$69.19M	$1.22	24.53	4.97	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)

Latest CDTX, COLL, MLYS, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
COLL Collegium Pharmaceutical	3.30	1.08	1.01
MLYS Mineralys Therapeutics	N/A	26.48	26.48
NTLA Intellia Therapeutics	N/A	4.90	4.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
COLL Collegium Pharmaceutical	N/A
MLYS Mineralys Therapeutics	84.46%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	7.64%
COLL Collegium Pharmaceutical	2.51%
MLYS Mineralys Therapeutics	33.24%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	12.21 million	11.28 million	No Data
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable

CDTX, COLL, MLYS, and NTLA Headlines

Recent News About These Companies

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by Brokerages

June 29 at 3:22 AM | marketbeat.com

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Nasdaq

June 27 at 4:48 PM | nasdaq.com

NTLA - Intellia Therapeutics Inc Chart - Morningstar

June 26, 2025 | morningstar.comM

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

June 25, 2025 | zacks.com

Intellia Therapeutics, Inc. (NTLA) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

NTLA Intellia Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.4% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

June 21, 2025 | finance.yahoo.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - What's Next?

June 20, 2025 | marketbeat.com

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 19, 2025 | finance.yahoo.com

Wedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)

June 18, 2025 | theglobeandmail.com

Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential

June 17, 2025 | msn.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's Why

June 17, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from Wedbush

June 16, 2025 | marketbeat.com

6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...

June 16, 2025 | benzinga.com

Intellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC Wainwright

June 16, 2025 | marketbeat.com

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

June 15, 2025 | globenewswire.com

Brokers Issue Forecasts for NTLA FY2026 Earnings

June 10, 2025 | marketbeat.com

Intellia Therapeutics Inc.

June 9, 2025 | barrons.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?

June 6, 2025 | marketbeat.com

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Tesla Bulls and Bears Collide: What Investors Should Know
By Sam Quirke | June 18, 2025
View Tesla Bulls and Bears Collide: What Investors Should Know

CDTX, COLL, MLYS, and NTLA Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$49.45 +1.42 (+2.96%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$48.83 -0.62 (-1.25%)

As of 04:43 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Collegium Pharmaceutical NASDAQ:COLL

$29.93 +0.03 (+0.10%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$30.34 +0.41 (+1.35%)

As of 04:03 AM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Mineralys Therapeutics NASDAQ:MLYS

$13.71 -0.29 (-2.07%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.76 +0.05 (+0.40%)

As of 04:00 AM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Intellia Therapeutics NASDAQ:NTLA

$9.56 -0.05 (-0.52%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.63 +0.07 (+0.77%)

As of 04:13 AM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time